Viking Therapeutics (VKTX) News Today $28.95 +0.60 (+2.12%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$28.90 -0.05 (-0.17%) As of 03/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Virtu Financial LLC Makes New $1.72 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Virtu Financial LLC bought a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 42,613 shares of the biotechnoloMarch 23 at 5:25 AM | marketbeat.comBetter Stock to Buy Right Now: Viking Therapeutics vs. Eli LillyMarch 23 at 4:43 AM | fool.comAmundi Sells 30,538 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Amundi trimmed its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 91.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,016 shares of the biotechnology company's stock after selling 30,538 shares during thMarch 23 at 3:19 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Buy" by AnalystsShares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have received a consensus rating of "Buy" from the thirteen analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, eleven have issued a buy recommendatMarch 23 at 2:35 AM | marketbeat.comMarketBeat Week in Review – 03/17 - 03/21 (VKTX)Stocks gained after the Fed meeting but drifted lower after disappointing guidance from FedEx; next week's inflation data is unlikely to provide needed clarityMarch 22 at 7:00 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 0% - Time to Sell?Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 0% - Here's What HappenedMarch 21 at 1:59 PM | marketbeat.comMagnetar Financial LLC Acquires New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)Magnetar Financial LLC acquired a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 48,102 shares of the biotechnology company's stock, valued at approximately $1,936,000. Several otherMarch 21 at 5:21 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 1% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Shares Down 1% - Should You Sell?March 20 at 2:40 PM | marketbeat.com1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall StreetMarch 20 at 7:19 AM | fool.comTocqueville Asset Management L.P. Invests $814,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)Tocqueville Asset Management L.P. acquired a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,230 shares of the biotechnology company's stock, valuedMarch 20 at 4:41 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Raised by Royce & Associates LPRoyce & Associates LP lifted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 464.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,261 shares of theMarch 20 at 4:22 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.6% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.6% - Here's WhyMarch 19, 2025 | marketbeat.comDown 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?March 19, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Shares Down 3.7% - Time to Sell?Viking Therapeutics (NASDAQ:VKTX) Trading Down 3.7% - What's Next?March 18, 2025 | marketbeat.comIs Viking Therapeutics the Next Blockbuster GLP-1 Stock?Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.March 18, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Charles Schwab Investment Management Inc. boosted its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 1.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owneMarch 18, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 1.6% - Should You Sell?Viking Therapeutics (NASDAQ:VKTX) Trading Down 1.6% - Should You Sell?March 17, 2025 | marketbeat.comRaymond James Financial Inc. Takes $24.89 Million Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Raymond James Financial Inc. bought a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 618,469 shares of the biotechnology compaMarch 16, 2025 | marketbeat.comMonimus Capital Management LP Makes New Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Monimus Capital Management LP acquired a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,006 shares of the bioteMarch 15, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 4.9% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Trading 4.9% Higher - Here's WhyMarch 14, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 137.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor ownedMarch 14, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 0.6% - Should You Sell?Viking Therapeutics (NASDAQ:VKTX) Trading Down 0.6% - What's Next?March 13, 2025 | marketbeat.comViking Therapeutics: No Buyout Needed NowMarch 13, 2025 | seekingalpha.comAGF Management Ltd. Boosts Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)AGF Management Ltd. lifted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 50.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 164,263 shares of the biotechnology company's stock aftMarch 13, 2025 | marketbeat.com1VKTX : Behind the Scenes of Viking Therapeutics's Latest Options TrendsMarch 13, 2025 | benzinga.comWhy Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today?March 13, 2025 | msn.comViking Therapeutics (NASDAQ:VKTX) Shares Up 8.8% - Still a Buy?Viking Therapeutics (NASDAQ:VKTX) Trading Up 8.8% - Here's What HappenedMarch 12, 2025 | marketbeat.comViking Therapeutics' new contract is a game changer. Here's how much money it could bring in.March 12, 2025 | marketwatch.comWhy Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock DroppedMarch 12, 2025 | fool.comViking manufacturing agreement removes key overhang, says Morgan StanleyMarch 12, 2025 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Viking Therapeutics (VKTX)March 12, 2025 | markets.businessinsider.comViking Therapeutics Is Ready For A Standalone FutureMarch 12, 2025 | seekingalpha.comBank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Bank of New York Mellon Corp boosted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 9.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 462,964 shares of the biotechnology company's stock after purchasing an additionMarch 12, 2025 | marketbeat.comCordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral FormulationsMarch 11, 2025 | finanznachrichten.deViking Therapeutics signs broad manufacturing agreement with CordenPharmaMarch 11, 2025 | markets.businessinsider.comViking supply pact may hurt takeover prospects, says William BlairMarch 11, 2025 | markets.businessinsider.comStellantis, Tesla, Viking Therapeutics: Market MinuteMarch 11, 2025 | finance.yahoo.comViking Therapeutics inks production deal for obesity drugMarch 11, 2025 | msn.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 9% - Time to Sell?Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 9% - What's Next?March 11, 2025 | marketbeat.comViking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)March 11, 2025 | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Down - What's Next?Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down - Should You Sell?March 11, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Tuesday.March 11, 2025 | marketbeat.comViking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735March 11, 2025 | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.3% - Time to Sell?Viking Therapeutics (NASDAQ:VKTX) Shares Down 2.3% - Here's WhyMarch 10, 2025 | marketbeat.comH.C. Wainwright says Novo results support Viking obesity potentialMarch 10, 2025 | markets.businessinsider.comViking Therapeutics (NASDAQ:VKTX) Trading Down 0.8% - Time to Sell?Viking Therapeutics (NASDAQ:VKTX) Trading Down 0.8% - What's Next?March 7, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 7.8% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Shares Up 7.8% - Here's What HappenedMarch 6, 2025 | marketbeat.comSteward Partners Investment Advisory LLC Acquires 66,358 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Steward Partners Investment Advisory LLC boosted its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 42.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 224,409 shares of the biotechnology company'March 6, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 2.9% - Time to Sell?Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 2.9% - Here's WhyMarch 5, 2025 | marketbeat.comViking Therapeutics (NasdaqCM:VKTX) Reports US$35M Q4 Loss As Stock Falls 12%March 4, 2025 | finance.yahoo.com Remove Ads Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Media Mentions By Week VKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VKTX News Sentiment▼1.010.64▲Average Medical News Sentiment VKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VKTX Articles This Week▼1716▲VKTX Articles Average Week Remove Ads Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Today Moderna News Today Viatris News Today Dr. Reddy's Laboratories News Today Ascendis Pharma A/S News Today Sarepta Therapeutics News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VKTX) was last updated on 3/23/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
